About CIPHARM
CIPHARM is a company based in Abidjan (Cote D'ivoire) founded in 1986. CIPHARM has raised $4.21 million across 1 funding round from investors including Cauris Management. CIPHARM offers products and services including Anti-Infectieux, Anti-Inflammatoires, Antigrippaux, Antihistaminiques, and Antipaludiques. CIPHARM operates in a competitive market with competitors including Akums, Jubilant Life Sciences, Recipharm, Unither and Nectar Lifesciences, among others.
- Headquarter Abidjan, Cote D'ivoire
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.21 M (USD)
in 1 rounds
-
Latest Funding Round
$4.21 M (USD), Private Equity Round
Apr 16, 2014
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CIPHARM
CIPHARM offers a comprehensive portfolio of products and services, including Anti-Infectieux, Anti-Inflammatoires, Antigrippaux, Antihistaminiques, and Antipaludiques.
Fights infections caused by microbes and viruses.
Reduces inflammation by blocking prostaglandin formation.
Treats and prevents influenza viruses effectively.
Blocks histamine receptors to alleviate allergic reactions.
Prevents and treats malaria through targeted therapy.
Funding Insights of CIPHARM
CIPHARM has successfully raised a total of $4.21M through 1 strategic funding round. The most recent funding activity was a Private Equity Round of $4.21 million completed in April 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CIPHARM
CIPHARM has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Cauris Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity buyouts and investments are pursued across multiple sectors.
|
Locked | Locked | Locked |
Investor details for CIPHARM
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CIPHARM
Investment portfolio details for CIPHARM
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CIPHARM
Detailed financials for CIPHARM
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cipharm Comparisons
Peer comparison for CIPHARM
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CIPHARM
CIPHARM operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Akums, Jubilant Life Sciences, Recipharm, Unither and Nectar Lifesciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
CDMO focusing on spectrum of dosage forms and therapeutic segments
|
|
| Locked | Locked | Locked |
Company offering a suite of R&D and manufacturing services for small molecules and generics
|
|
| Locked | Locked | Locked |
Pharmaceutical development and manufacturing services are offered contractually.
|
|
| Locked | Locked | Locked |
Contract development and manufacturing organization for proprietary and generic drugs
|
|
| Locked | Locked | Locked |
Cephalosporin APIs and generic formulations are manufactured.
|
|
| Locked | Locked | Locked |
CDMO with a focus on early phase drug product development
|
Detailed competitors of CIPHARM
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cipharm
Complete news archive for CIPHARM
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CIPHARM
CIPHARM was founded in 1986 and raised its 1st funding round 28 years after it was founded.
CIPHARM is headquartered in Abidjan, Cote D'ivoire.
CIPHARM is a funded company, having raised a total of $4.21M across 1 funding round to date.
CIPHARM was founded in 1986 and is based in Abidjan, Ivory Coast. Operations focus on the pharmaceutical sector, where finished formulations including tablets, capsules, syrups, and injectables are developed and produced. Therapeutic categories covered include antibiotics, analgesics, antipyretics, anti-infectives, gastrointestinal treatments, antihypertensives, antispasmodics, muscle relaxants, and additional areas. Manufacturing occurs locally to serve regional needs.
CIPHARM's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
CIPHARM offers Anti-Infectieux, Anti-Inflammatoires, Antigrippaux, Antihistaminiques, and Antipaludiques.
CIPHARM has 1 investor. Key investors include Cauris Management.